The effects of HIV/AIDS and antiretroviral drugs on vitamin D metabolism are still mostly unknown. This was a cross-sectional study to estimate the prevalence of vitamin D deficiency and identify its association with the clinical and metabolic parameters among 214 HIV-positive female patients on antiretroviral therapy (ART) in Brazil. The prevalence of vitamin D deficiency (< 30 ng/ml) was 40.65% (87/214). Hypercholesterolemia, high LDL-c, duration of use of current antiretroviral regimen, hypertriglyceridemia, body mass index, age, hypertension, time with AIDS ! 10 years and hyperglycemia were selected for multivariate analysis (p < 0.20). After this analysis, hypercholesterolemia and use of current antiretroviral regimen ! 3 years remained independently associated with vitamin D deficiency. There was an inverse statistically significant correlation between total cholesterol and serum 25(OH)D levels. High prevalence of vitamin D deficiency was found among HIV-positive women on ART and was independently associated with its prolonged use and with hypercholesterolemia.
Infection by HIV affects around 33 million people worldwide. The sociodemographic profile of this infection has been undergoing modifications, and nowadays, this disease affects 1.5 men for every woman, whereas a decade ago, it was 15 times more frequent among men. 1, 2 Over two thirds of newly infected people live in areas of extreme poverty, thus indicating increasing impoverishment associated with this infection and an important relationship with nutritional deficit. The lack of macronutrients has been associated with the worsening of the clinical manifestations of acquired immunodeficiency syndrome (AIDS) and increasing AIDS-related mortality. 1, 3, 4 However, few studies have examined serum 25-hydroxyvitamin D [25(OH)D] levels among HIV-infected patients or the effects of antiretroviral drugs on vitamin D metabolism. [3] [4] [5] Among HIV-positive patients, there would possibly be higher consumption of vitamin D by macrophages and lymphocytes. Immunological activity and the production of proinflammatory cytokines and tumor necrosis factor a (TNFa) may inhibit the active form of vitamin D in the kidneys. 3, 4, [6] [7] [8] diabetes, immune diseases, depression, hypertension, and cancer. [9] [10] [11] [12] [13] [14] Moreover, vitamin D has recently been indicated as an emerging biomarker for cardiovascular diseases. 12, 13 Advances in antiretroviral therapy (ART) have provided significant decreases in morbidity and mortality among patients with HIV, changing the clinical pattern of infection into a chronic disease. These patients are exposed to complications from the prolonged use of these drugs, particularly with regard to lipid and glucose metabolism, with recent reports of damage to bone metabolism. [15] [16] [17] [18] [19] Current epidemiological data indicate that vitamin D deficiency is reaching epidemic proportions, involving even healthy individuals in tropical, sunny regions. 9, 10, 20 ., 21 Therefore, vitamin D deficiency in this group of patients is a matter of concern and can worsen the possible complications from ART on bone and glucose-lipid metabolism, thereby increasing the risk of cardiovascular disease. Antiretroviral (ARV) medication probably act on cytochrome P450 to inhibit hydroxylation of vitamin D3 (cholecalciferol) in 25-hydroxyvitamin D preventing the activation of 1,25-dihydroxyvitamin D (calcitriol), and also increasing the catabolism of serum 25(OH)D. 4 The aim of the present study was to investigate the prevalence of vitamin D deficiency and its association with clinical and metabolic parameters among HIV-infected women using ARV medications.
Participants and Methods
This was a cross-sectional study that included women with HIV/AIDS who were attended at the Infectious Diseases outpatient service of the Oswaldo Cruz University Hospital between July 2007 and September 2008 and the Correia Picanço Hospital between January 2008 and November 2008.
It was conducted as part of the baseline evaluation of a cohort that was designed to investigate metabolic and cardiovascular disorders among individuals with HIV/AIDS in the state of Pernambuco / Brazil. This study was approved by the Research Ethics Committee of Oswaldo Cruz University Hospital (protocol number 127/2006).
Female individuals who had been on ART for a minimum of 6 months were included in the study. The exclusion criteria were as follows: patients who presented any disease that defines AIDS or any hospitalization over the 3-month period preceding the investigation; those with chronic use of corticosteroids, anticonvulsants, and/or rifampin over the 6-month period preceding the investigation; those with a clinical history of chronic diarrhea, hepatic disease, those with advanced chronic renal disease, primary hyperparathyroidism(all patients had normal serum calcium levels), and uncontrolled hypothyroidism or hyperthyroidism; pregnancy; and cases of active neoplasia, except for squamuos skin cell carcinoma.
Data Collection and Sample
Out of the total of 1594 patients in the cohort, there were 585 women. Of these, 317 met the inclusion criteria. There were 103 losses. Hence, 214 women participated in this study.
After signing the informed consent, the participants answered a standard questionnaire to collect demographic data, social data, personal and family history, along with questions on life habits and current medical treatments and questions directed toward HIV infection and associated diseases. Information on ART, CD4 curve, and occurrences of diseases that define AIDS were obtained from medical records.
Procedures and Techniques
Blood samples were collected after 12 hours of fasting. Serum total cholesterol, high-density lipoprotein cholesterol (HDL-c), triglycerides (TG), glucose and insulin were measured by colorimetric enzymatic method using Cobas Integra 400 II (Roche Diagnostics, Indianapolis-EUA). Low-density lipoprotein cholesterol (LDL-c) was calculated indirectly using the Friedewald formula. 22 The CD4 count was obtained by flow cytometry using the FACS Calibur 3-color method (Becton Dickinson, San Jose, EUA). Serum thyroid stimulating hormone (TSH) and intact parathyroid hormone (PTH) were measured by using chemiluminescence (ELESYS-Roche Diagnostics, Mannheim, Germany).
Serum 25(OH)D levels were measured using the chemiluminescence method-LIAISON (DiaSorin, Stillwater, USA), with the detection limited of 18 nmol/L (7 ng/mL), and the intra-assay and interassay coefficient of variation of 6.6% to 13% and 8% to 15%, respectively. Samples were obtained between July 2007 and November 2008. In Recife, serum 25(OH)D levels do not follow seasonal patterns because our region is located at the latitude of 10 south and is characterized by a hot and humid tropical climate, without great temperature variations and with abundance of sunlight throughout the year. 21 
Definition of Clinical Variables
Vitamin D deficiency was defined as serum 25(OH)D less than 30 ng/mL. 23 Hypercholesterolemia was defined as total cholesterol !200 mg/dL; hypertriglyceridemia was defined as TG values !150 mg/dL; high LDL-c levels were defined as !100 mg/dL and low HDL-c levels were defined as <50 mg/ dL. The reference value for considering PTH levels to be high was established as values above 65 pg/mL. Systemic arterial hypertension was defined as recorded systolic arterial pressure !140 mm Hg, recorded diastolic arterial pressure !90 mm Hg (taking the mean between initial and final measurements during the interview), or use of antihypertensive medication. 24 Metabolic syndrome (MS) was characterized using the modified NCEP-ATPIII (National Cholesterol Education Program-Adult Treatment Panel III) criteria and was defined as the presence of 3 or more of the following 5 criteria: TG !150 mg/dL; HDL-c < 50 mg/dL; fasting blood glucose !100 mg/dL or diabetes; blood pressure !130/85 mm Hg or use of antihypertensive medication; abdominal circumference !88 cm. 25, 26 The International Diabetes Federation (IDF) criteria were also used. 27 Insulin resistance was evaluated by means of the Homeostatic Model Assestment -Insulin Resistance (HOMA-IR) calculation. 28 To evaluate 10-year cardiovascular event risk, the Framingham and Prospective Cardiovascular Munster (PROCAM) scores were used. In accordance with these scores, patients were classified as low risk <10%, medium risk between 10 and 20% or high risk !20%. 29, 30 In relation to variables associated with HIV, duration of infection was defined as the time elapsed between the first positive serological test and the interview date. Diagnoses of AIDS referred to occurrences of AIDS-defining diseases that were confirmed by data in the medical records, using the Caracas and Center of Disease Control (CDC) criteria. 31 The time with ART was taken to be the time elapsed between first using ARV medications and the interview day. Current regimen was considered from the most recent regimen used. Both for HIV infection and for antiretroviral medication use, 3-year intervals were used for each category. Antiretroviral regimens were categorized into 3 groups: Nucleoside reverse transcriptase inhibitors (NRTI) associated with nonnucleoside reverse transcriptase inhibitors (NNRTI); NRTI associated with protease inhibitors (PI); and all 3 classes together. Lipodystrophy was defined by self-reporting, using an appropriate diagnostic questionnaire. 32 For physical activity, the International Physical Activity Questionnaire (IPAQ) model was used 33 and for alcohol consumption, the daily intake was quantified over the last 3 months by the modified World Health Organization (WHO) questionnaire. 34 Calcium intake was evaluated based on milk or dairy product consumption. 35 
Statistical Analysis
For descriptive analysis, the frequencies of the categorical variables were calculated, while means and standard deviations were calculated for continuous variables. Each variable was also correlated with vitamin D deficiency, and the magnitude of any associations was expressed in terms of the odds ratio. The statistical significance of the results obtained was evaluated using the confidence intervals of the estimated odds ratios, and P values were obtained using the w 2 test and maximum likelihood ratio. Pearson correlation coefficient was used to study associations between serum 25(OH)D levels and age, body mass index (BMI), blood pressure, total cholesterol, triglycerides, fasting glycemia, and PTH.
For multivariate analysis, multiple logistic regression was used (stepwise technique). Variables presenting P < .20 in univariate analysis were inserted in the model. In the final multivariate analysis, the variables that remained were those for which the association with vitamin D deficiency presented P < .10 or those that caused a change of 10% or more in the odds ratio values of the remaining variables, when inserted in the model. Data were stored in a database created for this particular research, employing the program FQL (Microsoft) Excel (Windows XP, Microsoft Office 2003). Stata 9.0 was employed for data analysis.
Results
The general characteristics of the study population are summarized in Table 1 . The mean age was 40.4 + 9.3 years, and 56.07% (120) were between 35 and 49 years. Mean age of Out of the total number of patients, 68.9% (131) had been diagnosed with AIDS for more than 3 years, while in 24 (11.2%) patients the time since the diagnosis was uncertain.
Median TCD4 lymphocyte cell count was 563 (17 to 1467) cells/mm 3 , and the median TCD4 nadir was 287 (3 to 1943) cells/mm 3 . Mean duration of ART was 4.8 + 3.15 years, and the mean length of use of the current regimen was 3.0 + 2.2 years. All except one of the participants were using NRTI, 50.9% (109) were using NNRTI, and 41.6% (89) were using an ARV regimen that contained PI.
Eight-three percent of the patients presented some abnormality of the lipid profile, with 58.9% (126) been diagnosed with lipodystrophy. Hypertension was found in 21.9% (47). There was a statistically significant inverse correlation between serum total cholesterol and serum 25(OH)D (r ¼ -.222; P ¼ .001) as demonstrated in Table 2 .
The comparison between the groups with and without vitamin D deficiency according to biological, socioeconomic, and life habit in univariate analysis shows that vitamin D deficiency was more frequent among women aged 50 or older (OR ¼ 2.15) than among younger women, although this was not statistically significant (P ¼ .082; OR ¼ 2.15 (0.90-5.10). Regarding anthropometric data, only BMI of 30 kg/m 2 or more was selected for multivariate analysis (P ¼ .116; OR ¼2.15 (0.82-5.59). In the univariate analysis, vitamin D deficiency did not present any association with physical activity, use of alcoholic drinks, or variables relating to dietary habits.
All the lipid profile parameters, with the exception of HDL-c, were selected for multivariate analysis, and hypercholesterolemia was stronger associated with vitamin D deficiency (P ¼ 0.013; OR ¼ 2.07; 1.16-3.70), in both univariate and multivariate analysis. There were no associations between vitamin D deficiency and diabetes or metabolic syndrome, using either the NCEP or the IDF criteria, insulin resistance, CVD absolute risk scores, and hypertension ( Table 3) .
The association between vitamin D levels and duration of antiretroviral therapy (P ¼ .057) was statistically significant and it remained in the final model of the multivariate analysis. Hypercholesterolemia, high LDL-c, duration of current ART, hypertriglyceridemia, BMI, age, hypertension, length of AIDS of 10 years or more, and hyperglycemia were included in the multivariate analysis model. Hypercholesterolemia and duration of current ARV regimen of 3 years or more remained independently associated with vitamin D deficiency (Table 4 ).
Discussion
The prevalence of vitamin D deficiency in our study was 40.65% (87/214), using a cutoff point of 30 ng/mL for serum 25(OH)D. There are few reports on the prevalence of vitamin D deficiency among HIV-infected patients, notably in the female population. This interest in the female gender is recent and has occurred since the change in the epidemiological profile of the disease with the alarming rate at which women have become affected. The natural history of HIV infection is still more comprehensively studied in male populations. 36, 37 A study carried out in the Netherlands with HIV-positive patients of both sexes reported a 58.1% prevalence of vitamin D deficiency in women with a mean age of 36.5 years, using the cutoff point for serum 25(OH)D of 10 ng/mL and 14 ng/mL for winter and summer, respectively. 5 Similar results were reported in a cross-sectional study on US sero-positive teenagers and young adults, employing a cutoff point for serum 25(OH)D of 15 ng/mL, demonstrating a prevalence of 87% of hypovitaminosis D. 6 On the other hand, Rodriguez et al, in the United States, showed a rate of vitamin D deficiency of 74.4% in HIV-positive adults of both sexes aged 46 years, when used the cutoff point of 32 ng/mL. 38 The results from these studies are in agreement with recent epidemiological studies, which point toward worldwide occurrence of vitamin D deficiency. 9, 10, 21 Several mechanisms have been suggested to explain vitamin D deficiency among patients with HIV: (a) the infection itself decreases the 1.25(OH) 2 D levels through the action of proinflammatory cytokines such as TNFa, which inhibits 25(OH)D hydroxylation; (b) consumption by macrophages and lymphocytes due to immunological activity caused by the disease; (c) the use of ART. Protease inhibitors can block hydroxylation of 25(OH)D and bioactivation of 1.25(OH) 2 D, 3, 4, 8 while NNRTIs increase the catabolism of 25(OH)D and 1.25(OH) 2 D. These drugs possibly act on the CYP450 cytochrome. 5, 8 In the present study, sunlight exposure was not evaluated, but it must be emphasized that our region is located at a tropical region (latitude of 10 South) without great temperature changes and with constant abundance of sunlight throughout the year, and that participants were predominantly in an age group that has daily activities both in open and in closed environments.
Although the data from this study suggested, from univariate analysis, that there was a negative association between serum 25(OH)D levels and BMI, this variable did not remain in the final model of the multivariate analysis. Both in an US cohort enrolling HIV-positive adolescents and young adults 6 and in the study by Kremer et al on healthy individuals, an association between serum 25(OH)D levels and BMI was reported. 14 In the present study, a lack of association would be expected since the population studied had a normal mean BMD and low rate of obesity.
No association was found between age and vitamin D deficiency, but the prevalence of vitamin D deficiency among women between 35 and 49 years of age was found to be 43.33%, thus inferring that vitamin D deficiency may occur earlier among HIV-positive patients using ARV medication. Among healthy American women in the age group of 20 to 39 years, the prevalence was also reported to be 18% in the National Health and Nutrition Survey (NHANES) III, using a cutoff point of 20 ng/mL for serum 25(OH)D. 39 There was no association between vitamin D deficiency and the duration of the diagnosis of HIV, as also described by Stephenson et al. 6 Lymphocytes CD4 counts greater than or less than 300 cells/mm 3 did not show any association with vitamin D deficiency. When the cutoff point of 100cells/mm 3 was used, this variable was selected for univariate analysis, but it did not remain in the final model. The association between vitamin D deficiency and immunity seems to be stronger at very low levels of CD4 or in cases of active disease. 7, 8 This result may be due to the fact that the patients were all using ARV medication, with a median CD4 count of 563 (17 to 1467) cells/mm 3 , thus showing a good immunological state.
After multivariate analysis, a significant association was found between high levels of total cholesterol and vitamin D deficiency. There was also an inverse correlation of serum 25(OH)D in relation to total cholesterol. Abnormalities in the lipid metabolism of HIV-infected patients are very prevalent. Firstly, increased triglyceride levels and decreased HDL-c and LDL-c levels were described at the more advanced stages of the disease. [15] [16] [17] 40 The action of the virus itself and of ARV medication in lipid metabolism, and particularly the action of PIs, may explain the high prevalence of dyslipidemia among these patients. According to Sankatsing et al, PIs inhibit degradation of sterol-responsive element-binding protein (SREBP 1) in adipocytes and hepatic cells. 41 Consequently, there is acceleration of hepatic synthesis of triglycerides and fatty acids. Protease inhibitors also act on LDL-c receptor, causing hypercholesterolemia, as well as inhibiting the protease that degrades apolipoprotein B (apoB), thereby increasing its availability to VLDL, while NNRTIs increase the hepatic synthesis of apoB. 40, 42 Furthermore, it has been suggested that after starting on ARV medication and with improvement in nutritional state, patients regain the lipid values prior to the disease. 40 These data suggest that ART may well interfere with steroid metabolism, thus contributing to vitamin D deficiency and elevated blood cholesterol levels.
We found an association between vitamin D deficiency and use of the current antiretroviral regimen for 3 years or more, independent of antiretroviral class. Treatment of AIDS using drug combinations has been found to be associated with various adverse effects such as lipodystrophy, dyslipidemia, and insulin resistance, which are known as typical risk factors for cardiovascular disease. [16] [17] [18] These abnormalities seem to be more pronounced in women and, after starting on ART, leading them to lose part of their natural estrogenic protection against atherosclerosis. 37 The results from the DAD Study, which included more than 22 000 HIV-positive patients who were using ARV medication, showed high frequency of hypertension, smoking, dyslipidemia, and diabetes in this population. Likewise, ARV medication was associated with 26% greater relative risk of myocardial infarction per year of exposure. 16, 18 Recent data from the cohort of the Framingham Offspring Study, in healthy individuals without renal disease or preexisting CVD, showed an association between vitamin D deficiency and increased risk of CVD, particularly among hypertensive individuals and in those with serum 25(OH)D levels less then 15 ng/mL, in which twice the risk of developing a cardiovascular event was found. 11 Therefore, the high prevalence of vitamin D deficiency among HIV-infected women undergoing ART, in a relatively young age group, may well contribute to a further increase in CVD risk.
In conclusion, the results from this study demonstrated a high prevalence of vitamin D deficiency among HIV-positive women on ART, which was independently associated with its prolonged used and with hypercholesterolemia. Since that vitamin D deficiency has been suggested as a possible risk condition for metabolic and cardiovascular events, the increased prevalence of this clinical condition in this population indicates the need for prevention. Vitamin D supplementation becomes necessary and/or sun exposure when the measurement of serum 25(OH)D is not feasible. Additional studies are clearly needed to validate the associations between vitamin D status and HIV disease progression as well the benefits of vitamin D in the cardiovascular system and endocrine metabolism in the HIV-infected patient.
